Xiong Yiquan, Chen Jingwen, Wu Yue, Zhao Peng, Liao Mingyu, Guo Jin, Liu Chunrong, Zheng Mengyuan, Ren Yan, Zou Kang, Sun Xin, Tan Jing
General Practice Medical Center, Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China.
EClinicalMedicine. 2025 Jul 31;86:103395. doi: 10.1016/j.eclinm.2025.103395. eCollection 2025 Aug.
Hypertensive disorders of pregnancy is a prevalent pregnancy complication worldwide, and the dose-response association between maternal pre-pregnancy body mass index (BMI) and hypertensive disorders of pregnancy has not been precisely studied. The aim of this study was to assess dose-response association between maternal pre-pregnancy BMI and hypertensive disorders of pregnancy, including pregnancy induced hypertension, preeclampsia and eclampsia.
This dose-response meta-analysis searched four electronic databases (Pubmed, Web of science, OVID Embase and OVID Medline) for relevant publications up to October, 2023. Cohort studies evaluated the association between pre-pregnancy or early pregnancy maternal BMI and pregnancy induced hypertension, preeclampsia, eclampsia and hypertensive disorders of pregnancy were included. Non-linear or linear dose-response association was modeled. Unadjusted and adjusted effects were pooled separately, and four subgroups, meta-regression, five sensitivity analyses were conducted. Study protocol was registered on the PROSPERO (CRD42022290318).
157 cohort studies involving 51,813,975 pregnancies were finally included. Of 157 studies, multiple outcomes were reported: 58 on pregnancy induced hypertension, 92 on preeclampsia, 6 on eclampsia, and 84 on hypertensive disorders of pregnancy, have assessed the association with pre-pregnancy BMI. A significant linear dose-response relationship was identified between BMI and pregnancy induced hypertension with a crude relative risk (cRR) of BMI per 5-unit increase of 1.73 (95% confidence intervals [CI]: 1.65-1.81), and an adjusted odds ratio (aOR) per 5-unit increase of 1.82 (95% CI: 1.74-1.90). Similar dose-response relationship was observed between BMI and preeclampsia (cRR: 1.63, 1.58-1.69; aOR: 1.70, 1.61-1.80), eclampsia (cRR: 1.40, 1.28-1.53; aOR: 1.36, 1.20-1.53) and hypertensive disorders of pregnancy (cRR: 1.68, 1.63-1.74; aOR: 1.75, 1.68-1.82). Subgroup analyses revealed that the pooled risk of BMI for pregnancy induced hypertension, preeclampsia, eclampsia, and hypertensive disorders of pregnancy was likely higher in Asian pregnant women compared to those in American and European regions. Sensitivity analyses results were mainly consistent with the primary results.
This meta-analysis demonstrated a clear and significant dose-response relationship between increasing maternal pre-pregnancy BMI and elevated risks of pregnancy induced hypertension, preeclampsia, eclampsia, and overall hypertensive disorders of pregnancy, underscoring the clinical importance of maintaining a healthy BMI prior to conception. Pre-pregnancy BMI may be an important focus for preconception counseling and subsequent pre-pregnancy weight management for both clinicians and women.
National Natural Science Foundation of China (72174132, 82474335, 82225049), Natural Science Foundation of Sichuan Province (2024NSFSC1668, 2024YFFK0152), 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD23004).
妊娠期高血压疾病是全球范围内常见的妊娠并发症,孕前母体体重指数(BMI)与妊娠期高血压疾病之间的剂量反应关系尚未得到精确研究。本研究旨在评估孕前母体BMI与妊娠期高血压疾病(包括妊娠高血压、子痫前期和子痫)之间的剂量反应关系。
本剂量反应荟萃分析检索了四个电子数据库(PubMed、Web of Science、OVID Embase和OVID Medline),以查找截至2023年10月的相关出版物。纳入了评估孕前或孕早期母体BMI与妊娠高血压、子痫前期、子痫及妊娠期高血压疾病之间关联的队列研究。建立了非线性或线性剂量反应模型。分别汇总未调整和调整后的效应,并进行了四个亚组分析、元回归分析和五项敏感性分析。研究方案已在PROSPERO(CRD42022290318)上注册。
最终纳入了157项队列研究,涉及51,813,975例妊娠。在157项研究中,报告了多个结局:58项关于妊娠高血压,92项关于子痫前期,6项关于子痫,84项关于妊娠期高血压疾病,并评估了与孕前BMI的关联。发现BMI与妊娠高血压之间存在显著的线性剂量反应关系,每增加5个单位BMI的粗相对风险(cRR)为1.73(95%置信区间[CI]:1.65-1.81),每增加5个单位的调整优势比(aOR)为1.82(95%CI:1.74-1.90)。在BMI与子痫前期(cRR:1.63,1.58-1.69;aOR:1.70,1.61-1.80)、子痫(cRR:1.40,1.28-1.53;aOR:1.36,1.20-1.53)和妊娠期高血压疾病(cRR:1.68,1.63-1.74;aOR:1.75,1.68-1.82)之间观察到类似的剂量反应关系。亚组分析显示,与美国和欧洲地区的孕妇相比,亚洲孕妇中BMI导致妊娠高血压、子痫前期、子痫和妊娠期高血压疾病的合并风险可能更高。敏感性分析结果与主要结果基本一致。
这项荟萃分析表明,孕前母体BMI升高与妊娠高血压、子痫前期、子痫及妊娠期高血压疾病总体风险升高之间存在明确且显著的剂量反应关系,强调了孕前保持健康BMI的临床重要性。孕前BMI可能是临床医生和女性孕前咨询及后续孕前体重管理的重要关注点。
中国国家自然科学基金(72174132、82474335、82225049)、四川省自然科学基金(2024NSFSC1668、2024YFFK0152)、四川大学华西医院学科卓越1.3.5项目(ZYGD23004)。